IL309085A - Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis - Google Patents
Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritisInfo
- Publication number
- IL309085A IL309085A IL309085A IL30908523A IL309085A IL 309085 A IL309085 A IL 309085A IL 309085 A IL309085 A IL 309085A IL 30908523 A IL30908523 A IL 30908523A IL 309085 A IL309085 A IL 309085A
- Authority
- IL
- Israel
- Prior art keywords
- osteoarthritis
- treatment
- dosing regimen
- nlrp3 inhibitor
- nlrp3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224890P | 2021-07-23 | 2021-07-23 | |
| PCT/IB2022/056695 WO2023002399A1 (en) | 2021-07-23 | 2022-07-20 | Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309085A true IL309085A (en) | 2024-02-01 |
Family
ID=82846336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309085A IL309085A (en) | 2021-07-23 | 2022-07-20 | Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250082611A1 (https=) |
| EP (1) | EP4373489A1 (https=) |
| JP (1) | JP2024525897A (https=) |
| KR (1) | KR20240038995A (https=) |
| CN (1) | CN117693340A (https=) |
| CA (1) | CA3224774A1 (https=) |
| IL (1) | IL309085A (https=) |
| WO (1) | WO2023002399A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65492B1 (sr) | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| CN112654350A (zh) * | 2018-07-03 | 2021-04-13 | 诺华股份有限公司 | 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法 |
| GB201916237D0 (en) * | 2019-11-07 | 2019-12-25 | Inflazome Ltd | Novel treatment |
-
2022
- 2022-07-20 IL IL309085A patent/IL309085A/en unknown
- 2022-07-20 KR KR1020247005666A patent/KR20240038995A/ko active Pending
- 2022-07-20 CN CN202280049591.4A patent/CN117693340A/zh active Pending
- 2022-07-20 EP EP22751844.6A patent/EP4373489A1/en active Pending
- 2022-07-20 JP JP2024503567A patent/JP2024525897A/ja active Pending
- 2022-07-20 US US18/580,781 patent/US20250082611A1/en active Pending
- 2022-07-20 WO PCT/IB2022/056695 patent/WO2023002399A1/en not_active Ceased
- 2022-07-20 CA CA3224774A patent/CA3224774A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023002399A1 (en) | 2023-01-26 |
| JP2024525897A (ja) | 2024-07-12 |
| KR20240038995A (ko) | 2024-03-26 |
| CA3224774A1 (en) | 2023-01-26 |
| EP4373489A1 (en) | 2024-05-29 |
| CN117693340A (zh) | 2024-03-12 |
| US20250082611A1 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL314033A (en) | Ras inhibitors | |
| DK4337652T3 (da) | NLRP3-hæmmere | |
| IL292643A (en) | Ras inhibitors | |
| IL292644A (en) | Ras inhibitors | |
| MA53388A (fr) | Inhibiteurs d'inflammasome nlrp3 | |
| DK4363406T3 (da) | Nlrp3-inflammasomhæmmere | |
| IL290845A (en) | Kras g12d inhibitors | |
| EP4192585A4 (en) | Kras g12d inhibitors | |
| EP4182313A4 (en) | KRAS-G12D INHIBITORS | |
| EP4240489A4 (en) | KRAS-G12D INHIBITORS | |
| CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
| IL287042A (en) | Inflammatory inhibitors of nlrp3 | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| IL284492B (en) | Beam information in early measurements | |
| LT3661921T (lt) | Selektyvūs nlrp3 inflamasomos inhibitoriai | |
| EP4051676A4 (en) | BCL-2 INHIBITORS | |
| EA201691421A1 (ru) | Гетероарилы и их применение | |
| IL283106A (en) | Erk inhibitors and uses thereof | |
| EP4136084A4 (en) | BCL-2 INHIBITOR | |
| EP3761992A4 (en) | ARGINASE INHIBITORS | |
| LT3405495T (lt) | Inhibitorių kelių neutralizavimas limfocituose | |
| SI3429571T1 (sl) | Kombinacije zaviralcev LSD1 za uporabo pri zdravljenju neoplastičnih bolezni | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |